Comparative efficacy and safety of vedolizumab and antitumor necrosis factor alfa in patients with inflammatory bowel diseases: A meta‑analysis
By:
References
- J. Torres, S. Mehandru, J. F. Colombel and L. Peyrin-Biroulet, Crohn’s disease, Lancet 389(10080) (2017) 1741–1755; https://doi.org/10.1016/s0140-6736(16)31711-1
- R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-Biroulet and J. F. Colombel, Ulcerative colitis, Lancet 389(10080) (2017) 1756–1770; https://doi.org/10.1016/s0140-6736(16)32126-2
- S. C. Ng, H. Y. Shi, N. Hamidi, F. E. Underwood, W. Tang, E. I. Benchimol, R. Panaccione, S. Ghosh, J. C. Y. Wu, F. K. L. Chan, J. J. Y. Sung and G. G. Kaplan, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies, Lancet 390(10114) (2017) 2769–2778; https://doi.org/10.1016/s0140-6736(1)32448-0
- S. Flynn and S. Eisenstein, Inflammatory bowel disease presentation and diagnosis, Surg. Clin. North Am. 99(6) (2019) 1051–1062; https://doi.org/10.1016/j.suc.2019.08.001
- L. Wang, Z. Jiang, M. Wang, F. Liu and L. Bai, Efficacy and safety of vedolizumab in patients with moderate-to-severe ulcerative colitis: A systematic review and meta-analysis, Chin. J. Gastroenter. 27 (2022) 32–38.
- G. Cui, Q. Fan, Z. Li, R. Goll and J. Florholmen, Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers, EBioMedicine 66 (2021) Article ID 103329 (9 pages); https://doi.org/10.1016/j.ebiom.2021.103329
- L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese, J. Guardiola, J. Jahnsen, C. Lees, E. Louis, M. Lukáš, W. Reinisch, X. Roblin, M. Jang, H. G. Byun, D.-H. Kim, S. J. Lee and R. Atreya, Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: A systematic review and meta-analysis, BMC Gastroenterol. 22(1) (2022) Article ID 291 (16 pages); https://doi.org/10.1186/s12876-022-02347-1
- V. Billioud, A. C. Ford, E. D. Tedesco, J. F. Colombel, X. Roblin and L. Peyrin-Biroulet, Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis, J. Crohns Colitis 7(11) (2013) 853–867; https://doi.org/10.1016/j.crohns.2013.01.014
- G. Mocci, M. Marzo, A. Papa, A. Armuzzi and L. Guidi, Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease, J. Crohns Colitis 7(10) (2013) 769–779; https://doi.org/10.1016/j.crohns.2013.01.009
- B. Qiu, J. X. Liang and C. Li, Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials, Medicine (Baltimore) 101(40) (2022) e30590; https://doi.org/10.1097/md.0000000000030590
- C. A. Lamb, N. A. Kennedy, T. Raine, P. A. Hendy, P. J. Smith, J. K. Limdi, B. Hayee, M. C. E. Lomer, G. C. Parkes, C. Selinger, K. J. Barrett, R. J. Davies, C. Bennett, S. Gittens, M. G. Dunlop, O. Faiz, A. Fraser, V. Garrick, P. D. Johnston, M. Parkes, J. Sanderson, H. Terry, D. R. Gaya, T. H. Iqbal, S. A. Taylor, M. Smith, M. Brookes, R. Hansen and A. B. Hawthorne, British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults, Gut 68(Suppl. 3) (2019) s1-s106; https://doi.org/10.1136/gutjnl-2019-318484
- G. D. Hahn, J. F. LeBlanc, P. A. Golovics, P. Wetwittayakhlang, A. Qatomah, A. Wang, L. Boodaghians, J. Liu Chen Kiow, M. Al Ali, G. Wild, W. Afif, A. Bitton, P. L. Lakatos and T. Bessissow, Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study, World J. Gastroenterol. 28(33) (2022) 4823–4833; https://doi.org/10.3748/wjg.v28.i33.4823
- R. Sablich, M. T. Urbano, M. Scarpa, F. Scognamiglio, A. Paviotti and E. Savarino, Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis, Sci. Rep. 13(1) (2023) Article ID 1816 (10 pages); https://doi.org/10.1038/s41598-023-28907-3
- L. Shamseer, D. Moher, M. Clarke, D. Ghersi, A. Liberati, M. Petticrew, P. Shekelle and L. A. Stewart, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: Elaboration and explanation, BMJ 350 (2015) g7647 (25 pages); https://doi.org/10.1136/bmj.g7647
- A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur. J. Epidemiol. 25(9) (2010) 603–605; https://doi.org/10.1007/s10654-010-9491-z
- A. R. Jadad, R. A. Moore, D. Carroll, C. Jenkinson, D. J. M. Reynolds, D. J. Gavaghan and H. J. Mc-Quay, Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Control. Clin. Trials 17(1) (1996) 1–12; https://doi.org/10.1016/0197-2456(95)00134-4
- X. Chen, M. Lu, W. Xu, X. Wang, M. Xue, J. Dai, Z. Zhang and G. Chen, Treatment of pediatric femoral shaft fractures with elastic stable intramedullary nails versus external fixation: A meta-analysis, Orthop. Traumatol. Surg. Res. 106(7) (2020) 1305–1311; https://doi.org/10.1016/j.otsr.2020.06.012
- J. A. C. Sterne, A. J. Sutton, J. P. A. Ioannidis, N. Terrin, D. R. Jones, J. Lau, J. Carpenter, G. Rücker, R. M. Harbord, C. H. Schmid, J. Tetzlaff, J. J. Deeks, J. Peters, P. Macaskill, G. Schwarzer, S. Duval, D. G. Altman, D. Moher and J. P. Higgins, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ 343 (2011) Article ID d4002 (8 pages); https://doi.org/10.1136/bmj.d4002
- T. Adar, D. Faleck, S. Sasidharan, K. Cushing, N. Z. Borren, N. Nalagatla, R. Ungaro, W. Sy, S. C. Owen, A. Patel, B. L. Cohen and A. N. Ananthakrishnan, Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly ibd patients: A multicentre study, Aliment. Pharmacol. Ther. 49(7) (2019) 873–879; https://doi.org/10.1111/apt.15177
- C. Allamneni, K. Venkata, H. Yun, F. Xie, L. DeLoach and T. A. Malik, Comparative effectiveness of vedolizumab vs. Infliximab induction therapy in ulcerative colitis: Experience of a real-world cohort at a tertiary inflammatory bowel disease center, Gastroenterol. Res. 11(1) (2018) 41–45; https://doi.org/10.14740/gr934w
- M. Bohm, R. Xu, Y. Zhang, S. Varma, M. Fischer, G. Kochhar, B. Boland, S. Singh, R. Hirten, R. Ungaro, E. Shmidt, K. Lasch, V. Jairaith, D. Hudesman, S. Chang, D. Lukin, A. Swaminath, B. E. Sands, J. F. Colombel, S. Kane, E. V. Loftus, Jr., B. Shen, C. A. Siegel, W. J. Sandborn and P. S. Dulai, Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease, Aliment. Pharmacol. Ther. 52(4) (2020) 669–681; https://doi.org/10.1111/apt.15921
- B. Bokemeyer, S. Plachta-Danielzik, R. di Giuseppe, P. Efken, W. Mohl, M. Hoffstadt, T. Krause, A. Schweitzer, E. Schnoy, R. Atreya, N. Teich, L. Trentmann, R. Ehehalt, P. Hartmann and S. Schreiber, Real-world effectiveness of vedolizumab vs anti-TNF in biologic-naïve Crohn’s disease patients: A 2-year propensity-score-adjusted analysis from the VEDOIBD-study, Inflamm. Bowel Dis. 30(5) (2024) 746–756; https://doi.org/10.1093/ibd/izad138
- B. Bokemeyer, S. Plachta-Danielzik, R. di Giuseppe, P. Efken, W. Mohl, T. Krause, M. Hoffstadt, R. Ehehalt, L. Trentmann, A. Schweitzer, P. Jessen, P. Hartmann and S. Schreiber, Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study, Aliment. Pharmacol. Ther. 58(4) (2023) 429–442; https://doi.org/10.1111/apt.17616
- B. Bressler, A. Yarur, M. S. Silverberg, M. Bassel, E. Bellaguarda, C. Fourment, A. Gatopoulou, P. Karatzas, U. Kopylov, G. Michalopoulos, S. Michopoulos, U. Navaneethan, D. T. Rubin, J. Siffledeen, A. Singh, K. Soufleris, D. Stein, D. Demuth and G. J. Mantzaris, Vedolizumab and anti-tumour necrosis factor α real-world outcomes in biologic-naïve inflammatory bowel disease patients: Results from the evolve study, J. Crohns Colitis 15(10) (2021) 1694–1706; https://doi.org/10.1093/ecco-jcc/jjab058
- A. Cassinotti, N. Mezzina, A. De Silvestri, D. Di Paolo, M. V. Lenti, C. Bezzio, D. Stradella, M. Mauri, V. Zadro, C. Ricci, V. Casini, E. Radice, A. Massari, G. Maconi, S. Saibeni, F. Caprioli, R. Tari, M. Fichera, C. C. Cortelezzi, M. Parravicini, C. Tinelli, P. A. Testoni, F. Pace, S. Segato, P. Invernizzi, P. Occhipinti, G. Manes, A. Di Sabatino, L. Pastorelli, M. Vecchi and S. Ardizzone, Continuous clinical remission with biologics in ulcerative colitis: The ‘aurora’ comparison study, Eur. J. Gastroenterol. Hepatol. 34(12) (2022) 1238–1246; https://doi.org/10.1097/meg.0000000000002443
- R. S. Dalal, E. L. McClure, J. Marcus and J. R. Allegretti, Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naïve patients with ulcerative colitis, Dig. Dis. Sci. 68(1) (2023) 223–232; https://doi.org/10.1007/s10620-022-07472-1
- F. D’Amico, L. Massimino, G. Palmieri, A. Dal Buono, R. Gabbiadini, B. Caron, P. Moreira, I. Silva, M. Bosca-Watts, T. Innocenti, G. Dragoni, C. Bezzio, A. Zilli, F. Furfaro, S. Saibeni, M. Chaparro, M. J. García, G. Michalopoulos, N. Viazis, G. J. Mantzaris, P. Ellul, J. P. Gisbert, F. Magro, L. Peyrin-Biroulet, A. Armuzzi, F. Ungaro, S. Danese, G. Fiorino and M. Allocca, An international multicentre study of switching from intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel diseases: The time study, Eur. J. Clin. Invest. 54(11) (2024) e14283; https://doi.org/10.1111/eci.14283
- R. Davis, P. McParland, S. Dodd, D. Storey, C. Probert, P. Collins, T. Skouras, A. Steel, E. Derbyshire, M. Dibb and S. Subramanian, Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis, Eur. J. Gastroenterol. Hepatol. 31(6) (2019) 661–667; https://doi.org/10.1097/meg.0000000000001395
- A. Favale, S. Onali, F. Caprioli, D. Pugliese, A. Armuzzi, F. S. Macaluso, A. Orlando, A. Viola, W. Fries, A. Rispo, F. Castiglione, G. Mocci, F. Chicco, P. Usai, E. Calabrese, L. Biancone, G. Monteleone and M. C. Fantini, Comparative efficacy of vedolizumab and adalimumab in ulcerative colitis patients previously treated with infliximab, Inflamm. Bowel Dis. 25(11) (2019) 1805–1812; https://doi.org/10.1093/ibd/izz057
- A.-L. Gagnon, W. Beauchesne, L. Tessier, C. David, D. Berbiche, A. Lavoie, A. Michaud-Herbst and K. Tremblay, Adalimumab, infliximab, and vedolizumab in treatment of ulcerative colitis: A long-term retrospective study in a tertiary referral center, Crohn’s Colitis 360 3(4) (2021) Article ID otab049 (9 pages); https://doi.org/10.1093/crocol/otab049
- Z. Huang, J. Tang, R. Wu, S. Long, W. Chen, T. Lu, Q. Xia, Y. Wu, H. Yang, Q. Yang, Z. Huang, Q. Guo, M. Li, X. Gao and K. Chao, Comparison of clinical and endoscopic efficacy between vedolizumab and infliximab in bio-naïve patients with ulcerative colitis: A multicenter, real-world study, Therap. Adv. Gastroenterol. 17 (2024) 1–13; https://doi.org/10.1177/17562848241281218
- M. Hupé, P. Rivière, S. Nancey, X. Roblin, R. Altwegg, J. Filippi, M. Fumery, G. Bouguen, L. Peyrin-Biroulet, A. Bourreille, L. Caillo, M. Simon, F. Goutorbe and D. Laharie, Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: A multicentre cohort study, Aliment. Pharmacol. Ther. 51(9) (2020) 852–860; https://doi.org/10.1111/apt.15680
- T. Innocenti, J. Roselli, E. N. Lynch, P. Apolito, L. Parisio, S. Bagnoli, G. Macrì, F. Rogai, M. Tarocchi, S. Milani, A. Galli, M. Milla and G. Dragoni, Infectious risk of vedolizumab compared with other biological agents in the treatment of inflammatory bowel disease, Eur. J. Gastroenterol. Hepatol. 33(1S) (2021) e574–e579; https://doi.org/10.1097/meg.0000000000002166
- M. J. Kim, Y. J. Kim, D. Jeong, S. Kim, S. Hong, S. H. Park and K. W. Jo, Comparative risk of serious infections and tuberculosis in Korean patients with inflammatory bowel disease treated with non-anti-TNF biologics or anti-TNF-α agents: A nationwide population-based cohort study, Therap. Adv. Gastroenterol. 17 (2024) 1–14; https://doi.org/10.1177/17562848241265013
- M. D. Long, T. W. Smith, M. Dibonaventura, D. Gruben, D. Bargo, L. Salese and D. Quirk, Real-world effectiveness of advanced therapies among patients with moderate to severe ulcerative colitis in the United States, Inflamm. Bowel Dis. 26(6) (2020) 941–948; https://doi.org/10.1093/ibd/izz204
- D. Lukin, D. Faleck, R. Xu, Y. Zhang, A. Weiss, S. Aniwan, S. Kadire, G. Tran, M. Rahal, A. Winters, S. Chablaney, J. L. Koliani-Pace, J. Meserve, J. P. Campbell, G. Kochhar, M. Bohm, S. Varma, M. Fischer, B. Boland, S. Singh, R. Hirten, R. Ungaro, K. Lasch, E. Shmidt, V. Jairath, D. Hudesman, S. Chang, A. Swaminath, B. Shen, S. Kane, E. V. Loftus, Jr., B. E. Sands, J. F. Colombel, C. A. Siegel, W. J. Sandborn and P. S. Dulai, Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis, Clin. Gastroenterol. Hepatol. 20(1) (2022) 126–135; https://doi.org/10.1016/j.cgh.2020.10.003
- F. S. Macaluso, M. Ventimiglia, W. Fries, A. Viola, M. Cappello, B. Scrivo, A. Magnano, D. Pluchino, S. Camilleri, S. Garufi, R. D. Mitri, F. Mocciaro, G. Magrì, C. Ferracane, M. Citrano, F. Graziano, C. Bertolami, S. Renna, R. Orlando, G. Rizzuto, M. Cottone and A. Orlando, A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis, Dig. Liver Dis. 52(12) (2020) 1461–1466; https://doi.org/10.1016/j.dld.2020.06.014
- F. S. Macaluso, M. Ventimiglia, W. Fries, A. Viola, A. Sitibondo, M. Cappello, B. Scrivo, A. Busacca, A. C. Privitera, S. Camilleri, S. Garufi, R. Di Mitri, F. Mocciaro, N. Belluardo, E. Giangreco, C. Bertolami, S. Renna, R. Orlando, G. Rizzuto, M. Cottone and A. Orlando, A propensity score weighted comparison of vedolizumab and adalimumab in Crohn’s disease, J. Gastroenterol. Hepatol. 36(1) (2021) 105–111; https://doi.org/10.1111/jgh.15107
- R. P. Meng, B. B. Huang, Y. L. Wei, L. Lyu, H. Yang, C. Liu, H. L. Zhou, X. P. Liao, J. Y. Zhou and X. Xie, Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study, J. Dig. Dis. 25(4) (2024) 230–237; https://doi.org/10.1111/1751-2980.13270
- A. Moens, B. Verstockt, D. Alsoud, J. Sabino, M. Ferrante and S. Vermeire, Translating results from varsity to real world: Adalimumab vs vedolizumab as first-line biological in moderate to severe IBD, Inflamm. Bowel Dis. 28(8) (2022) 1135–1142; https://doi.org/10.1093/ibd/izab257
- B. S. Pabla, C. Alex Wiles, J. C. Slaughter, E. A. Scoville, R. L. Dalal, D. B. Beaulieu, D. A. Schwartz and S. N. Horst, Safety and efficacy of vedolizumab versus tumor necrosis factor α antagonists in an elderly ibd population: A single institution retrospective experience, Dig. Dis. Sci. 67(7) (2022) 3129–3137; https://doi.org/10.1007/s10620-021-07129-5
- H. Patel, D. Latremouille-Viau, R. Burne, S. Shi and S. Adsul, Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease, Crohn’s Colitis 360 1(2) (2019) Article ID otz022 (9 pages); https://doi.org/10.1093/crocol/otz022
- R. Roberti, L. F. Iannone, C. Palleria, C. De Sarro, R. Spagnuolo, M. A. Barbieri, A. Vero, A. Manti, V. Pisana, W. Fries, G. Trifirò, M. D. Naturale, T. Larussa, A. E. De Francesco, V. Bosco, E. Donato di Paola, R. Citraro, F. Luzza, L. Bennardo, S. Rodinò, P. Doldo, E. Spina, E. Russo and G. De Sarro, Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigi-lance study in southern italy, Curr. Med. Res. Opin. 36(9) (2020) 1457–1463; https://doi.org/10.1080/03007995.2020.1786681
- B. E. Sands, L. Peyrin-Biroulet, E. V. Loftus, Jr., S. Danese, J. F. Colombel, M. Törüner, L. Jonaitis, B. Abhyankar, J. Chen, R. Rogers, R. A. Lirio, J. D. Bornstein and S. Schreiber, Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis, N. Engl. J. Med. 381(13) (2019) 1215–1226; https://doi.org/10.1056/NEJMoa1905725
- M. Shehab, A. Alfadhli, I. Abdullah, W. Alostad, A. Marei and F. Alrashed, Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study), Front. Pharmacol. 15 (2024) Article ID 1388043 (8 pages); https://doi.org/10.3389/fphar.2024.1388043
- S. Singh, A. T. Iversen, K. H. Allin and T. Jess, Comparative outcomes and safety of vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases, JAMA Netw. Open 5(9) (2022) e2234200; https://doi.org/10.1001/jamanetworkopen.2022.34200
- M. Tallarico, C. Palleria, L. Ruffolo, R. Spagnuolo, M. D. Naturale, A. E. De Francesco, C. De Sarro, R. Romeo, R. Citraro, P. Doldo, L. Abenavoli, L. Gallelli, F. Luzza, A. Leo and G. De Sarro, Biologics for inflammatory bowel disease in clinical practice: A Calabria (Southern Italy) prospective pharmacovigilance study, Pharmaceutics 14(11) (2022) Article ID 2449 (11 pages); https://doi.org/10.3390/pharmaceutics14112449
- K. Wagner, T. M. Müller, F. Vitali, S. Fischer, S. Haberkamp, R. Rouse-Merkel, R. Atreya, M. F. Neurath and S. Zundler, Treatment trajectories and outcomes in inflammatory bowel disease: a tertiary single--centre experience, Therap. Adv. Gastroenterol. 17 (2024) 1–14; https://doi.org/10.1177/17562848241284051
- C. Guo, K. Wu, X. Liang, Y. Liang and R. Li, Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis, Pharmacol. Res. 148 (2019) Article ID 104455; https://doi.org/10.1016/j.phrs.2019.104455
- E. V. Loftus, Jr., B. G. Feagan, R. Panaccione, J. F. Colombel, W. J. Sandborn, B. E. Sands, S. Danese, G. D’Haens, D. T. Rubin, I. Shafran, A. Parfionovas, R. Rogers, R. A. Lirio and S. Vermeire, Long-term safety of vedolizumab for inflammatory bowel disease, Aliment. Pharmacol. Ther. 52(8) (2020) 1353–1365; https://doi.org/10.1111/apt.16060
- A. Cholapranee, G. S. Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet and A. N. Ananthakrishnan, Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in crohn’s disease and ulcerative colitis controlled trials, Aliment. Pharmacol. Ther. 45(10) (2017) 1291–1302; https://doi.org/10.1111/apt.14030
- V. Jairath, K. Chan, K. Lasch, S. Keeping, C. Agboton, A. Blake and H. Patel, Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: A network meta-analysis, Expert Rev. Gastroenterol. Hepatol. 15(6) (2021) 711–722; https://doi.org/10.1080/17474124.2021.1880319
- S. Singh, M. Fumery, W. J. Sandborn and M. H. Murad, Systematic review with network meta--analysis: First- and second-line pharmacotherapy for moderate-severe ulcerative colitis, Aliment. Pharmacol. Ther. 47(2) (2018) 162–175; https://doi.org/10.1111/apt.14422
- M. E. de Jong, L. J. T. Smits, B. van Ruijven, N. den Broeder, M. G. V. M. Russel, T. E. H. Römkens, R. L. West, J. M. Jansen and F. Hoentjen (on behalf of IBDREAM), Increased discontinuation rates of anti-TNF therapy in elderly inflammatory bowel disease patients, J. Crohn’s Colitis 14(7) (2020) 888–895; https://doi.org/10.1093/ecco-jcc/jjaa012
- C. Harris and J. R. F. Cummings, JAK1 inhibition and inflammatory bowel disease, Rheumatology (Oxford) 60(Suppl. 2) (2021) ii45–ii51; https://doi.org/10.1093/rheumatology/keaa896
- W. J. Sandborn, S. Vermeire, L. Peyrin-Biroulet, M. C. Dubinsky, J. Panes, A. Yarur, T. Ritter, F. Baert, S. Schreiber, S. Sloan, F. Cataldi, K. Shan, C. J. Rabbat, M. Chiorean, D. C. Wolf, B. E. Sands, G. D’Haens, S. Danese, M. Goetsch and B. G. Feagan, Etrasimod as induction and maintenance therapy for ulcerative colitis (elevate): Two randomised, double-blind, placebo-controlled, phase 3 studies, Lancet 401(10383) (2023) 1159–1171; https://doi.org/10.1016/s0140-6736(23)00061-2
- Z. Tian, Q. Zhao and X. Teng, Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease, Front. Immunol. 15 (2024) Article ID 1393463 (8 pages); https://doi.org/10.3389/fimmu.2024.1393463
Language: English
Page range: 23 - 40
Accepted on: Jan 20, 2025
Published on: Apr 10, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2025 Yafang Li, Jin Ding, Chong Lu, Yiping Hong, Qunying Wang, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.